Cargando…

Research progress on criteria for discontinuation of EGFR inhibitor therapy

The clinical success of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) as therapeutic agents has prompted great interest in their further development and clinical testing for a wide variety of malignancies. However, most studies have focused on the efficacy of TKI, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhuang, Hong-qing, Yuan, Zhi-yong, Wang, Jun, Wang, Ping, Zhao, Lu-jun, Zhang, Bai-lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475392/ https://www.ncbi.nlm.nih.gov/pubmed/23082072 http://dx.doi.org/10.2147/OTT.S36103

Ejemplares similares

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
por: Inzoli, Elena, et al.
Publicado: (2022)

Contraction criteria for incremental stability of differential systems with discontinuous right-hand sides()
por: Lang, Yingying, et al.
Publicado: (2022)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Progressive alveolar echinococcosis after discontinuation of anthelmintic therapy
por: Meilinger, Michael, et al.
Publicado: (2013)

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
por: Zhong, Hua, et al.
Publicado: (2023)

Research progress of berberine mediated photodynamic therapy
por: An, Ya-Wen, et al.
Publicado: (2021)

Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation
por: Zhuang, Hongqing, et al.
Publicado: (2016)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
por: Sharma, Rohini, et al.
Publicado: (2022)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
por: Wang, Qiming, et al.
Publicado: (2019)

The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro
por: Zhuang, Hong-Qing, et al.
Publicado: (2009)

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
por: Zhao, Ben, et al.
Publicado: (2016)

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
por: Yang, Yudie, et al.
Publicado: (2022)

The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MET-PI3K-AKT signal transduction
por: Zhuang, Hong-Qing, et al.
Publicado: (2013)

Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody
por: Zhuang, Hong-Qing, et al.
Publicado: (2014)

The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

CALM1 promotes progression and dampens chemosensitivity to EGFR inhibitor in esophageal squamous cell carcinoma
por: Liu, Tao, et al.
Publicado: (2021)

Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy
por: Sebastian, Agata, et al.
Publicado: (2017)

Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors
por: Chim, Kannie, et al.
Publicado: (2013)

Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis
por: Zhuang, Jingqi, et al.
Publicado: (2017)

Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

Radiomic Feature-Based Nomogram: A Novel Technique to Predict EGFR-Activating Mutations for EGFR Tyrosin Kinase Inhibitor Therapy
por: Weng, Qiaoyou, et al.
Publicado: (2021)

A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors
por: Li, Qing, et al.
Publicado: (2016)

Anti‐inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy
por: Li, Yuyu, et al.
Publicado: (2021)

Research progress of diabetic retinopathy and gut microecology
por: Wang, Rui, et al.
Publicado: (2023)

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
por: Wang, Jun, et al.
Publicado: (2016)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

The efficacy and safety of immune checkpoint inhibitors for patients with EGFR‐mutated non‐small cell lung cancer who progressed on EGFR tyrosine‐kinase inhibitor therapy: A systematic review and network meta‐analysis
por: Wang, Zhen, et al.
Publicado: (2023)

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations
por: Gao, Yuan, et al.
Publicado: (2017)

The Role and Research Progress of Inhibitor of Differentiation 1 in Atherosclerosis
por: Qiu, Jun, et al.
Publicado: (2022)

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2020)

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer
por: Zhu, Jian, et al.
Publicado: (2012)

EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR
por: Wang, Anbang, et al.
Publicado: (2020)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study
por: Huang, Chu-Ying, et al.
Publicado: (2015)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan, Jiadi, et al.
Publicado: (2021)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

The efficacy of laparoscopic cholecystectomy without discontinuation in patients on antithrombotic therapy
por: Yun, Jong Hyuk, et al.
Publicado: (2017)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_c1kk1lagiqdareq5k3a11og0uo